dc.contributor.author | Executive Board, 140 | en_US |
dc.coverage.spatial | Geneva | en_US |
dc.date.accessioned | 2018-07-24T13:09:53Z | |
dc.date.available | 2018-07-24T13:09:53Z | |
dc.date.issued | 2017 | |
dc.identifier.govdoc | EB140/23 Add.1 | |
dc.identifier.uri | https://iris.who.int/handle/10665/273266 | |
dc.description | 1 p. | en_US |
dc.language.iso | en | en_US |
dc.publisher | World Health Organization | en_US |
dc.subject.mesh | Pharmaceutical Preparations | en_US |
dc.subject.mesh | Drug Contamination | en_US |
dc.subject.mesh | Fraud | en_US |
dc.subject.mesh | Drug Industry | en_US |
dc.title | Member State mechanism on substandard/ spurious/falsely-labelled/falsified/ counterfeit medical products: draft decision | en_US |
dc.type | Governing body documents | en_US |
who.relation.languageVersion | 10665/273267 | en_US |
who.relation.languageVersion | 10665/273268 | en_US |
who.relation.languageVersion | 10665/273269 | en_US |
who.relation.languageVersion | 10665/273270 | en_US |
who.relation.languageVersion | 10665/273271 | en_US |